<DOC>
	<DOCNO>NCT00003172</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different combination combine interferon alfa G-CSF may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness different combination chemotherapy regimens treat patient advanced stomach cancer .</brief_summary>
	<brief_title>Comparison Combination Chemotherapy Regimens Treating Patients With Advanced Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate objective response rate two different regimen patient advance gastric cancer : combination fluorouracil plus hydroxyurea give high dose 24 hour infusion plus interferon alfa-2a filgrastim ; versus combination doxorubicin docetaxel . II . Evaluate toxicity reversibility toxicity combination patient advance gastric cancer . OUTLINE : This open label , two arm , multicenter , randomize study . Arm I : Patients receive fluorouracil ( 5-FU ) , recombinant alfa-2a interferon , hydroxyurea ( HU ) , filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) . 5-FU administer 24 hour infusion day 1 , 8 , 15 , 22 , 29 , 36 ( week 1-6 ) . Recombinant alfa-2a interferon administer subcutaneously immediately begin 5-FU infusion , three time week 6 week . HU administer 24 hour infusion day 1 , 8 , 15 , 22 , 29 , 36 ( week 1-6 ) . G-CSF administer subcutaneously day 3 , 4 , 5 , 6 week 1-6 . Weeks 7 8 rest period . Arm II : Patients receive doxorubicin administer slow IV push follow ( 30 minute infusion ) docetaxel 1 hour IV infusion . Treatment repeat every 21 day . All patient assess monthly study continue study treatment long disease progression unacceptable toxic effect observe . Patients follow every 3 month first 2 year , every 6 month year 2-5 , annually thereafter . PROJECTED ACCRUAL : A minimum 26 patient ( 13 arm ) maximum 80 patient ( 40 arm ) accrue study approximately 2 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma stomach gastroesophageal junction beyond scope surgical resection Must measurable disease either one two dimension either radiographically physical examination Measurable disease must document outside prior radiation portal Evaluable disease allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm3 Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 1.5 time ULN Alkaline phosphatase great 5 time ULN Renal : Creatinine le 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No chronic unstable angina No uncontrolled congestive heart failure No arrhythmia No chronic angina No myocardial infarction past 1 year If history atherosclerotic heart disease , prior cardiac catheterization thallium stress test must suggest coronary artery disease Neurology : No symptomatic peripheral neuropathy great grade 2 No cerebellar disease No seizure disorder No organic mental syndrome No major psychoaffective disorder Pulmonary : No chronic obstructive pulmonary disease No chronic bronchitis , emphysema , sarcoid , bronchiectasis Other : No poorly control diabetes mellitus No psychiatric illness No active infection , include AIDS , ARC , HIV positive No history hypersensitivity product contain Polysorbate 80 No history uncontrolled alcohol drug abuse No uncontrolled hypercalcemia No prior malignancy within past 5 year nonmelanomatous skin cancer cervical carcinoma situ Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior systemic chemotherapy Endocrine therapy : No chronic use steroids No concurrent hormonal therapy ( except birth control pill ) Radiotherapy : At least 1 month since prior radiotherapy No concurrent palliative radiotherapy ( arm I patient ) Surgery : Must fully recover surgery Other : At least 4 week since investigational agent recover toxic effect No chronic use aspirin , nonsteroidal antiinflammatory agent , antianginal medication , extraordinary antihypertensive regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
</DOC>